It looks like this is the end of the line for BioSante as we know it. After dissapointing results from a phase 3 trial when BioSante's lead drug, LibiGel, failed to beat a placebo, shares cratered and never recovered. Now comes today's news that BioSante will be merging with ANI Pharmaceuticals, with ANI gaining control of the company. This video takes a closer look at the merger and what it means for investors.

Many investors are attracted to BioSante and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.